|
Krystal Biotech, Inc. (KRYS) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Krystal Biotech, Inc. (KRYS) Bundle
Explorez les perspectives financières de Krystal Biotech, Inc. (KRYS) avec notre calculatrice DCF conviviale! Entrez vos projections pour la croissance, les marges et les dépenses pour calculer la valeur intrinsèque de Krystal Biotech, Inc. (KRYS) et améliorez votre stratégie d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 50.7 | 290.5 | 363.1 | 453.9 | 567.4 | 709.3 | 886.6 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 473.02 | 25 | 25 | 25 | 25 | 25 |
| EBITDA | -30.3 | -65.3 | -145.2 | 17.9 | 109.9 | 271.0 | 338.8 | 423.5 | 529.3 | 661.6 |
| EBITDA, % | 100 | 100 | 100 | 35.31 | 37.83 | 74.63 | 74.63 | 74.63 | 74.63 | 74.63 |
| Depreciation | 1.9 | 2.8 | 4.1 | 5.0 | 6.7 | 226.7 | 283.4 | 354.3 | 442.8 | 553.6 |
| Depreciation, % | 100 | 100 | 100 | 9.88 | 2.31 | 62.44 | 62.44 | 62.44 | 62.44 | 62.44 |
| EBIT | -32.2 | -68.1 | -149.3 | 12.9 | 103.2 | 262.2 | 327.7 | 409.6 | 512.0 | 640.0 |
| EBIT, % | 100 | 100 | 100 | 25.44 | 35.52 | 72.19 | 72.19 | 72.19 | 72.19 | 72.19 |
| Total Cash | 271.3 | 438.1 | 379.2 | 532.2 | 597.5 | 363.1 | 453.9 | 567.4 | 709.3 | 886.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | 42.0 | 104.7 | 304.3 | 380.4 | 475.5 | 594.3 | 742.9 |
| Account Receivables, % | 100 | 100 | 100 | 82.92 | 36.06 | 83.8 | 83.8 | 83.8 | 83.8 | 83.8 |
| Inventories | .0 | .0 | .0 | 7.0 | 26.5 | 234.5 | 293.1 | 366.4 | 458.0 | 572.6 |
| Inventories, % | 100 | 100 | 100 | 13.78 | 9.12 | 64.58 | 64.58 | 64.58 | 64.58 | 64.58 |
| Accounts Payable | 2.1 | 8.4 | 4.0 | 1.8 | 5.0 | 221.8 | 277.2 | 346.5 | 433.2 | 541.5 |
| Accounts Payable, % | 100 | 100 | 100 | 3.65 | 1.72 | 61.07 | 61.07 | 61.07 | 61.07 | 61.07 |
| Capital Expenditure | -14.8 | -68.3 | -53.0 | -11.8 | -4.2 | -18.0 | -22.5 | -28.1 | -35.1 | -43.9 |
| Capital Expenditure, % | 100 | 100 | 100 | -23.27 | -1.46 | -4.95 | -4.95 | -4.95 | -4.95 | -4.95 |
| Tax Rate, % | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 | 6.5 |
| EBITAT | -32.2 | -68.1 | -149.3 | 10.9 | 96.5 | 250.8 | 313.5 | 391.8 | 489.8 | 612.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -43.1 | -127.4 | -202.6 | -47.0 | 19.9 | 268.8 | 495.2 | 619.0 | 773.7 | 967.1 |
| WACC, % | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2,391.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 986 | |||||||||
| Terminal Value | 16,445 | |||||||||
| Present Terminal Value | 11,193 | |||||||||
| Enterprise Value | 13,585 | |||||||||
| Net Debt | -338 | |||||||||
| Equity Value | 13,922 | |||||||||
| Diluted Shares Outstanding, MM | 30 | |||||||||
| Equity Value Per Share | 468.13 |
What You Will Get
- Real Krystal Biotech Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Krystal Biotech, Inc. (KRYS).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Krystal Biotech.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Krystal Biotech’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Krystal Biotech, Inc. (KRYS).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Krystal Biotech.
Key Features
- Customizable Growth Metrics: Adjust vital inputs such as revenue projections, R&D spending, and operational costs.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Results: Leverages Krystal Biotech's actual financial data for accurate valuation insights.
- Effortless Scenario Analysis: Easily explore various assumptions and evaluate their impact on results.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Krystal Biotech data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Krystal Biotech’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Krystal Biotech, Inc. (KRYS)?
- Accuracy: Utilizes real Krystal Biotech financial data for precise calculations.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected at the CFO level.
- User-Friendly: Designed for ease of use, suitable for those without extensive financial modeling skills.
Who Should Use Krystal Biotech, Inc. (KRYS)?
- Investors: Gain insights into innovative therapies with a reliable valuation tool.
- Financial Analysts: Streamline your analysis process with a customizable DCF model tailored for biotech.
- Consultants: Effortlessly modify the template for client reports or presentations in the biotech sector.
- Biotech Enthusiasts: Enhance your knowledge of biotech valuation methods through practical examples.
- Educators and Students: Utilize it as a hands-on resource for finance and biotech courses.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Krystal Biotech historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Krystal Biotech, Inc. (KRYS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.